Clinical Trials Browser

Phase 2 × zipalertinib × Clear all

NCT05967689 2026-04-03

REZILIENT2

Phase 2 Recruiting

Carcinoma, Lung Diseases

NCT07229339 2026-02-05

Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Lung Non-Squamous Non-Small Cell Carcinoma